Immunovant (IMVT) concentration risks

The company's concentration profile is defined by a single pipeline asset and a single device supplier, both carrying high disclosed size and both with meaningful dependency dimensions. Following a decision to discontinue further development of batoclimab across all indications, the company has focused fully on IMVT-1402, creating a high-share product concentration with a mixed character. The structural component reflects a deliberate strategic refocus; the idiosyncratic component reflects the binary nature of clinical and regulatory outcomes for a single program. With no approved product and no advanced backup asset disclosed, the company's near-term value is almost entirely determined by IMVT-1402's clinical and commercial trajectory. Compounding that pipeline concentration is a high-share dependency on Ypsomed AG, whose YpsoMate autoinjector is the intended commercial delivery device for IMVT-1402 in all ongoing studies. The character is dependency: the company cannot commercialize or even complete clinical evaluation of IMVT-1402 without Ypsomed's device, meaning that a manufacturing failure, pricing dispute, or regulatory issue at the device supplier level could independently delay or derail the program. The two exposures are tightly coupled — both are linked to a single asset — which means an adverse outcome at either the drug or device level converges on the same point of failure. This is the most important variable to monitor in the company's risk profile.

For the engine’s reasoning on IMVT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.